Scope 2024: Driving Innovation in Clinical Trials and Digital Health

By Rob Wilson

Scope 2024: Driving Innovation in Clinical Trials and Digital Health — Sticky
Top 10 Trends for Improving Clinical Trials Using DHTs in 2024

At the 15th Annual SCOPE Meeting in Orlando, “Driving Innovation in Clinical Trials and Digital Health,” representatives from across the clinical trial ecosystem shared case studies and described their commitment to improving patient health through better clinical trials.

SCOPE recognizes the importance of clinical trials and research in advancing medical knowledge, improving patient care, and developing new treatments. Thus, collaboration, innovation, and strategic decision-making are crucial.

Here are ten key takeaways from industry leaders about using DHTs and digital measurement to improve patient outcomes:

  1. Progress in Digital Health Technologies: Representatives from ABBVIE, BMS, Roche, Genentech, J&J, Pfizer, BI, and others discussed the value of DHTs and improved digital measures.
  2. Early Design Phase: Therefore, consider novel digital endpoints early in the design phase and protocol development.
  3. Measure What Matters: Focus on what matters to patients and avoid using technology for its own sake.
  4. Patient-Centric Design: Moreover, engage patients in design to develop measures that improve clinical outcomes.
  5. Efficiency in Clinical Trials: Consequently, use DHTs and novel digital endpoints to reduce sample sizes and shorten development cycles.
  6. Holistic View: Measure patient function in real-world, real-time, and continuous ways for a more comprehensive view than episodic, on-site clinic measures.
  7. FDA Support: The FDA supports using DHTs and digital measurement solutions. They offer guidance on decentralized and hybrid clinical trials.
  8. ROI and eNPV Enhancement: Additionally, Tufts Center for Drug Development and DiMe presented data showing how DHTs can enhance the ROI and eNPV of clinical trials.
  9. NIH Funding: The NIH consistently funds developments to improve the use of digital technology in clinical trials.
  10. Pharma Innovation: Consequently, pharma sponsors invest in innovation and patient engagement teams. They share lessons and incorporate digitally derived endpoints across the development enterprise.

In conclusion, VivoSense is dedicated to improving clinical trials. Contact our team to collaborate on developing digital endpoints that can enhance clinical trial efficiency, efficacy, and patient outcomes.

Read More